Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Completed No phase listed Observational Results available

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

NCT05340751
View directory record Official record
Conditions
Anesthesia
Interventions
Blood drawn
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
40 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 21, 2026, 1:42 PM EDT
Terminated Phase 2 Interventional Results available

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
Biological · Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

Red Cell Transfusion Goals in Patients With Acute Leukemias

NCT02086773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Massive Iron Deposit Assessment

NCT01572922
View directory record Official record
Conditions
Iron Overload, Excessive Body Iron Burden
Interventions
R2*-UTE, R2*-GRE, Liver biopsy
Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 1:42 PM EDT
Completed No phase listed Observational

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

NCT05255445
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Pediatric Cancer
Interventions
Red Blood Cell (RBC) Transfusion
Biological
Lead sponsor
Westat
Other
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

NCT00968227
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Vasospasm
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 21, 2026, 1:42 PM EDT
Withdrawn Phase 1 Interventional

Autologous Cell Therapy After Stroke

NCT00908856
View directory record Official record
Conditions
Stroke
Interventions
autologous bone marrow mononuclear cell transfusion, marrow stromal cells, placebo
Biological · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041
View directory record Official record
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome

NCT00621023
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Decitabine, Arsenic Trioxide and Ascorbic Acid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Leucovorin for the Treatment of 5 q Minus Syndrome

NCT00004997
View directory record Official record
Conditions
5q Minus Syndrome, Myelodysplastic Syndrome
Interventions
Leucovorin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 1:42 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

NCT00306150
View directory record Official record
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 1:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

State Of The Art Functional Imaging In Sickle Cell Disease

NCT01137721
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 19 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 21, 2026, 1:42 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Investigations of Fetal Anesthesia During Maternal Fetal Surgery

NCT07571811
View directory record Official record
Conditions
Fetal Anesthesia
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 1:42 PM EDT
Completed No phase listed Observational

PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions

NCT02087553
View directory record Official record
Conditions
Iron, Abnormal Blood Level
Interventions
Transfusion of red blood cells, Infusion of albumin/saline
Biological
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 21, 2026, 1:42 PM EDT
Recruiting Not applicable Interventional

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

NCT03204357
View directory record Official record
Conditions
Cardiac Disease, Bleeding Postoperative
Interventions
Fresh Autologous whole Blood, Standard of Care Expectant management of bleeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

FM 140 vs FM100 Study in Patients With Multiple Myeloma

NCT00505895
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Fludarabine, Stem Cell Infusion, Rituximab
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Not applicable Interventional

San Diego Bleeding Esophageal Varices Study

NCT00690027
View directory record Official record
Conditions
Survival and Control of Bleeding
Interventions
Emergency portacaval shunt, Emergency and long-term endoscopic sclerotherapy
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

NCT00442702
View directory record Official record
Conditions
Anemia
Interventions
Mircera, Darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
11
States / cities
Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Results available

The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants

NCT00167388
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
feed during blood transfusion
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Weeks to 38 Weeks
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Transfusion Ratio of Fresh Frozen Plasma (FFP) to Packed Red Blood Cell (PRBC) During Burn Excision and Grafting

NCT05063409
View directory record Official record
Conditions
Burn Injury
Interventions
Treatment
Other
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 3 Interventional

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

NCT00003593
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
asparaginase, cytarabine, daunorubicin hydrochloride, methotrexate, therapeutic hydrocortisone, thioguanine
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Safety Study for Beta Thalassemia Subjects on PTG-300

NCT04054921
View directory record Official record
Conditions
β-thalassemia, Ineffective Erythropoiesis
Interventions
PTG-300
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 21, 2026, 1:42 PM EDT
Completed Phase 4 Interventional Results available

Effects of Microplegia on Transfusion Rates After Cardiac Surgery

NCT05076604
View directory record Official record
Conditions
Aortic Valve Disease, Mitral Valve Disease
Interventions
Cardioplegia Solution, Microplegic Solution No. 1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 1:42 PM EDT